Despite success of optimal medical therapy for coronary heart disease, currently there is no doubt regarding efficiency of interventional procedures. However, much controversy exists for myocardial protection regarding possible damage during elective percutaneous coronary intervention (PCI).
The aim – to investigate the effects of rosuvastatin and trimetazidine (in combination or separately) as cardioprotective agents during planned PCI.
Results. Under rosuvastatin (group B) and combined treatment (group C) 24 hours after PCI periprocedural myocardial damage incidence was 11.1 %, which was significantly lower than in the control group (45.7 %, Р=0.001) and group D (37.5 %, Р=0.062), which received only trimetazidine for medical correction.
Conclusion. Summarizing on the prevalence of periprocedural myocardial injury after 12 and 24 hours, we noted anti-ischemic cardioprotective effects during PCI only for rosuvastatin or its combination with trimetazidine, compared with other groups studied. Isolated use of trimetazidine was associated with a significant decrease in absolute levels of TnI only in groups of patients with evidence of myocardial injury during PCI.